论文部分内容阅读
口服或静脉应用非诺多潘(Fenoldopam)具有扩张肾脏与全身血管作用,该药刺激突触后多巴胺受体。与多巴胺不同,该药无明显增强α或β-肾上腺素能活性作用;较大剂量也不直接增加心率或血压。非诺多潘可降低外周阻力,增加心脏指数、心率、搏出量与左室射血率。早期的研究提示多巴胺-1促效剂对伴有肾衰或充血性心力衰竭的高血压患者较适用,近期发现给高血压患者静脉应用非诺多潘时清除半衰期<10分钟,因此对急性高血压进行静脉治疗是合适的。本文作者评价非诺多潘对各种伴有重度或进行性高血压的住院患者进行静脉治疗的作用。
Oral or intravenous application of fenoldopam has the potential to expand renal and systemic vascularization, which stimulates postsynaptic dopamine receptors. Unlike dopamine, this drug did not significantly potentiate α or β-adrenergic activity; higher doses did not directly increase heart rate or blood pressure. Fenostatin reduces peripheral resistance and increases cardiac index, heart rate, stroke volume, and left ventricular ejection rate. Early studies suggest that dopamine-1 agonist is more suitable for hypertensive patients with renal failure or congestive heart failure, recently found to hypertensive patients with intravenous fenofovanx clearance half-life <10 minutes, so the acute high Blood pressure for intravenous treatment is appropriate. The authors evaluated the effect of fenotorp on venous treatment in a variety of hospitalized patients with severe or progressive hypertension.